Mishani Eyal, Hagooly Aviv
Cyclotron Unit, Department of Nuclear Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
J Nucl Med. 2009 Aug;50(8):1199-202. doi: 10.2967/jnumed.109.062117. Epub 2009 Jul 17.
A wealth of research has focused on developing targeted cancer therapies by specifically inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). However, the outcome of most EGFR-TK-targeted drugs that were approved by the Food and Drug Administration or entered clinical trials has been only moderate. Enhancement of EGFR-targeted therapy hinges on a reliable in vivo quantitative molecular imaging method. Such a method would enable monitoring of receptor drug binding and receptor occupancy in vivo; determination of the duration of EGFR inhibition in vivo; and, potentially, identification of a primary or secondary mutation in EGFR leading to drug interaction or loss of EGFR recognition by the drug. This review analyzes the most recent strategies to visualize and quantify EGFR-TK in cancer by nuclear medicine imaging and describes future directions.
大量研究致力于通过特异性抑制表皮生长因子受体酪氨酸激酶（EGFR-TK）来开发靶向癌症疗法。然而，大多数已获美国食品药品监督管理局批准或进入临床试验的EGFR-TK靶向药物的疗效仅为中等。增强EGFR靶向治疗取决于一种可靠的体内定量分子成像方法。这种方法将能够监测体内受体与药物的结合以及受体占有率；确定体内EGFR抑制的持续时间；并且有可能识别导致药物相互作用或药物无法识别EGFR的EGFR原发性或继发性突变。本综述分析了通过核医学成像可视化和量化癌症中EGFR-TK的最新策略，并描述了未来的方向。
